NCT01893099View on ClinicalTrials.gov

Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

November 28, 2017

Study Completion Date

November 28, 2017

Conditions
Ocular Melanoma
Interventions
DRUG

Sorafenib

Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.

DEVICE

Radioembolization with SIR-Spheres® (Yttrium Microspheres)

Trial Locations (1)

Unknown

Centre Hospitalier Universitaire Vaudois, Lausanne

All Listed Sponsors
lead

Centre Hospitalier Universitaire Vaudois

OTHER

NCT01893099 - Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma | Biotech Hunter | Biotech Hunter